Elizabeth Chacko, DO
Endocrinology, Diabetes & Metabolism · Baltimore, MDNPI 1528337391
Payments from drug & device makers
Across 65 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$267
- Corcept Therapeutics$164
- Novo Nordisk$119
- Radius Health, Inc.$101
- Xeris Pharmaceuticals, Inc.$93
- Dexcom, Inc.$82
- plus $578 from 16 others
What the payments were for
- Food & beverage$1,404100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 11 | $267 |
| Corcept Therapeutics | 7 | $164 |
| Novo Nordisk | 7 | $119 |
| Radius Health, Inc. | 3 | $101 |
| Xeris Pharmaceuticals, Inc. | 5 | $93 |
| Dexcom, Inc. | 4 | $82 |
| Tandem Diabetes Care, Inc. | 4 | $77 |
| Boehringer Ingelheim | 3 | $72 |
| Insulet Corporation | 4 | $57 |
| AstraZeneca(2 entities) | 3 | $50 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Medtronic | 2 | $42 |
| BD | 1 | $39 |
| Embecta Corp. | 1 | $32 |
| Bayer | 1 | $25 |
| Novartis | 1 | $24 |
| Abbott | 1 | $21 |
| AbbVie | 1 | $20 |
| Lifescan, Inc. | 1 | $19 |
| Nevro Corp. | 1 | $18 |
| Amgen | 1 | $17 |
| Cequr Corporation | 1 | $16 |
How this compares
$1,404 in reported general payments places this provider in the 45th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 239 | $418,386 |
| JardianceEmpagliflozin | 126 | $162,896 |
| TrulicityDulaglutide | 68 | $134,976 |
| MounjaroTirzepatide | 64 | $112,409 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $83,671 |
| FarxigaDapagliflozin Propanediol | 43 | $57,971 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $49,986 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $47,533 |
| RybelsusSemaglutide | 11 | $29,533 |
| Humalog Kwikpen U-100Insulin Lispro | 44 | $18,401 |
| JanuviaSitagliptin Phosphate | 20 | $15,535 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $15,408 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $14,816 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 85 | $10,583 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 27 | $9,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $119 | $447,919250 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $267 | $247,385132 claims |
| Boehringer IngelheimJardiance | $72 | $162,896126 claims |
| AstraZenecaFarxiga | $50 | $57,97143 claims |
| AbbVieSynthroid | $20 | $4,85279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Baltimore
- Jean ParkBaltimore$3.7M
- Ilias SpanakisBaltimore$2.6M
- Philip LevinBaltimore$702K
- Roberto SalvatoriBaltimore$403K
- Thomas DonnerBaltimore$197K
- Adrian DobsBaltimore$190K
- Todd BrownBaltimore$143K
- Nowreen HaqBaltimore$85K
- Nanette SteinleBaltimore$74K
- Paul SackBaltimore$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.